Crystalline forms of Acalabrutinib
The present invention provides crystalline forms of Acalabrutinib, Specific crystalline forms provided by the present invention include Acalabrutinib Form APO-I, a co-crystal of Acalabrutinib and urea; APO-II, a co-crystal of Acalabrutinib and nicotinamide; APO-III, a co-crystal of Acalabrutinib and L-sorbitol; APO-IV, a crystalline form of Acalabrutinib; and APO-V, a co-crystal of Acalabrutinib and urea.
1. A crystalline form of Acalabrutinib that is a co-crystal of Acalabrutinib and urea, wherein the molar ratio of Acalabrutinib to urea is between approximately 1:1.5 and approximately 1:2.5.
2. The co-crystal of claim 1 , wherein the molar ratio of Acalabrutinib to urea is approximately 1:2.
3. The co-crystal of claim 1 , characterized by a PXRD diffractogram comprising peaks, expressed in degrees 2θ (±0.2°), at 5.4°, 7.3° and 10.0°.
4. The co-crystal of claim 3 , further comprising at least three peaks, expressed in degrees 2θ (±0.2°), selected from the group consisting of: 10.4°, 11.4°, 11.8°, 12.8°, 15.3°, 17.0°, 18.4°, 20.1°, 20.8° and 21.3°.
5. The co-crystal of claim 3 , further comprising peaks, expressed in degrees 2θ (±0.2°), at 10.4°, 11.4°, 11.8°, 12.8°, 15.3°, 17.0°, 18.4°, 20.1°, 20.8° and 21.3°.
6. The co-crystal of claim 1 characterized by a PXRD diffractogram comprising peaks, expressed in degrees 2θ (±0.2°), at 5.4°, 6.6° and 11.0°.
7. The co-crystal of claim 6 , further comprising at least three peaks, expressed in degrees 2θ (±0.2°), selected from the group consisting of: 10.1°, 13.2°, 15.1°, 17.3°, 19.9°, 21.1° and 22.2°.
8. The co-crystal of claim 6 , further comprising peaks, expressed in degrees 2θ (±0.2°), at 10.1°, 13.2°, 15.1°, 17.3°, 19.9°, 21.1° and 22.2°.
9. A pharmaceutical composition comprising the crystalline form of Acalabrutinib according to claim 1 , and one or more pharmaceutically acceptable excipients.